title: Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma.
abstract: Accumulating evidence indicates that the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway plays a key role in esophageal carcinogenesis. A better understanding of the pathway downstream of COX-2 may reveal novel targets for the prevention of esophageal adenocarcinoma (EAC). The objective of this study was to characterize the profile of genes involved in PGE2 metabolism and signaling in an experimental model of EAC. Esophagojejunostomy with gastric preservation was performed in wistar rats to induce gastroduodenal reflux. Rats were sacrificed 2 or 4 months after surgery. Nine non-operated rats were used to obtain normal (control) esophageal tissues.
  
  
  RESULTS
  All rats that underwent esophagojejunostomy developed inflammation. In addition, 90% of the animals showed intestinal metaplasia; of those, 40% progressed to AC. This process was accompanied by a significant increase in esophageal PGE2 levels and the induction of both mRNA and protein levels of COX-2, COX-1, prostaglandin E synthase, 15-hydroxyprostaglandin dehydrogenase, and PGE2 receptors EP3, EP4 and especially EP2, which rose to particularly high levels in experimental rats. In addition, exposure to a selective COX-2 inhibitor (SC58125) or an EP1/EP2 antagonist (AH6809), but not an EP4 antagonist (AH23848B), significantly reduced cell proliferation of esophageal explants in 24 hour-organ culture experiments. Our data suggest that, in addition to COX-2, other components of the PGE2 pathway, including COX-1, may play important roles in the development of EAC induced by gastroduodenal reflux in the rat. Although it must be confirmed in vivo, the EP2 receptor may represent a promising selective target in the prevention of Barrett's associated AC.
authors.affiliation: IIS Aragon, Aragon Institute of Health Scineces, Zaragoza, Spain. epiazor@unizar.es
authors.forename: E
authors.initials: E
authors.lastname: Piazuelo
authors.forename: S
authors.initials: S
authors.lastname: Santander
authors.forename: C
authors.initials: C
authors.lastname: Cebrián
authors.forename: P
authors.initials: P
authors.lastname: Jiménez
authors.forename: C
authors.initials: C
authors.lastname: Pastor
authors.forename: M A
authors.initials: MA
authors.lastname: García-González
authors.forename: F
authors.initials: F
authors.lastname: Esteva
authors.forename: P
authors.initials: P
authors.lastname: Esquivias
authors.forename: J
authors.initials: J
authors.lastname: Ortego
authors.forename: A
authors.initials: A
authors.lastname: Lanas
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D015153:Blotting, Western; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism*; D004195:Disease Models, Animal; D004938:Esophageal Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006911:Hydroxyprostaglandin Dehydrogenases / Q000378:metabolism; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone